AVONEX
AVONEX (interferon beta-1a) is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients. The therapy is used to manage various stages of the disease, including clinically isolated syndrome and relapsing-remitting disease. It is also indicated for patients with active secondary progressive disease. As a member of the interferon beta class, it serves as a therapeutic option for adults experiencing these specific relapsing forms of MS.
How AVONEX Works
AVONEX is classified as an interferon beta. The specific mechanism of action by which the drug exerts its therapeutic effects in patients with multiple sclerosis is currently unknown. While the drug is used to treat relapsing forms of the disease, the precise biological pathways involved in its efficacy have not been established.
Details
- Status
- Prescription
- First Approved
- 1996-05-17
- Routes
- N/A
- Dosage Forms
- VIAL
AVONEX Approval History
What AVONEX Treats
1 indicationsAVONEX is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Sclerosis
Drugs Similar to AVONEX
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
AVONEX FDA Label Details
ProIndications & Usage
FDA Label (PDF)AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.